Identifies OXA-48 variants impacting antimicrobial resistance in Enterobacterales, suggesting targeted prevention strategies.
Since their first identification in Türkiye in 2001, OXA-48-like carbapenemases have posed diagnostic challenges due to variant-specific phenotypic and resistance profiles. We investigated the distribution of OXA-48 variants and their association with antimicrobial susceptibility, carbapenem minimum inhibitory concentrations (MICs), phenotypic detection performance, and single- or dual-carbapenemase production. A total of 703 clinical carbapenem-resistant Enterobacterales isolates recovered over 5 years were included. Identification and antimicrobial susceptibility testing were performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and an automated system; carbapenem MICs by broth microdilution; carbapenemase genes by multiplex qPCR; and OXA-48 variants by sequence analysis. CNPt-direct and mCIM were performed for OXA-48 variants. OXA-48-like, NDM, and KPC carbapenemases were detected in 52.3%, 11.7%, and 11.5% of isolates, respectively, with co-production observed in 11.7% of OXA-48-like–positive isolates. The most common OXA-48 variants were OXA-48/245 (39.1%), OXA-232 (36.4%), and OXA-181 (17.6%), while OXA-244, OXA-162, and OXA-1200 were less frequent. This study represents the first report of the OXA-1200 variant from Türkiye. OXA-48/245 was the variant most commonly co-produced with other carbapenemases, whereas OXA-244 predominated among CNPt-direct–negative isolates. Susceptibility to meropenem and imipenem among OXA-48-like producers was 31% and 39.1%, respectively, with higher carbapenem MIC 50 values observed for OXA-181, OXA-232, and OXA-48/245 compared to OXA-244. In K. pneumoniae , meropenem resistance rates were higher with OXA-48/245, OXA-232, and OXA-181 than with other variants. MIC 50 values of carbapenem were higher in dual carbapenemase producers compared to single carbapenemase producers. Our findings show that OXA-48 variants significantly impact resistance profiles, MIC values, and the sensitivity of phenotypic tests and detection of co-produced carbapenemases. Understanding their regional distribution is crucial for targeted prevention strategies.
No takes yet. Share an insight, caveat, or question.
Arduç et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: